JP2023515915A5 - - Google Patents

Info

Publication number
JP2023515915A5
JP2023515915A5 JP2022538283A JP2022538283A JP2023515915A5 JP 2023515915 A5 JP2023515915 A5 JP 2023515915A5 JP 2022538283 A JP2022538283 A JP 2022538283A JP 2022538283 A JP2022538283 A JP 2022538283A JP 2023515915 A5 JP2023515915 A5 JP 2023515915A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
intestinal
subject
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022538283A
Other languages
English (en)
Japanese (ja)
Other versions
JP7665215B2 (ja
JP2023515915A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2020/051746 external-priority patent/WO2021119827A1/en
Publication of JP2023515915A publication Critical patent/JP2023515915A/ja
Publication of JP2023515915A5 publication Critical patent/JP2023515915A5/ja
Application granted granted Critical
Publication of JP7665215B2 publication Critical patent/JP7665215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022538283A 2019-12-19 2020-12-18 腸のニューロパチーを治療するためのグリア細胞株由来神経栄養因子（ｇｄｎｆ）の使用 Active JP7665215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950781P 2019-12-19 2019-12-19
US62/950,781 2019-12-19
PCT/CA2020/051746 WO2021119827A1 (en) 2019-12-19 2020-12-18 Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Publications (3)

Publication Number Publication Date
JP2023515915A JP2023515915A (ja) 2023-04-17
JP2023515915A5 true JP2023515915A5 (cg-RX-API-DMAC7.html) 2023-12-13
JP7665215B2 JP7665215B2 (ja) 2025-04-21

Family

ID=76476522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538283A Active JP7665215B2 (ja) 2019-12-19 2020-12-18 腸のニューロパチーを治療するためのグリア細胞株由来神経栄養因子（ｇｄｎｆ）の使用

Country Status (6)

Country Link
US (1) US20230022970A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076499B1 (cg-RX-API-DMAC7.html)
JP (1) JP7665215B2 (cg-RX-API-DMAC7.html)
CA (1) CA3162011A1 (cg-RX-API-DMAC7.html)
ES (1) ES3036928T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021119827A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240366723A1 (en) * 2021-06-16 2024-11-07 Transfert Plus, Limited Partnership Combination therapy for the treatment of enteric neuropathies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
CA2422707A1 (en) 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
BR0206919A (pt) 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
UA112981C2 (uk) * 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
US20160045487A1 (en) * 2013-03-27 2016-02-18 Childeren's Medical Center Corporation Compositions and methods for treating neuropathy
EP3414322A4 (en) * 2015-12-23 2020-03-04 Memorial Sloan-Kettering Cancer Center CELL THERAPY AND DRUG DISCOVERY BASED ON CELL LINES DERIVED FROM HUMAN ENTERAL NEURAL CREST DERIVED FROM PLURIPOTENT STEM CELLS

Similar Documents

Publication Publication Date Title
CN102718858B (zh) 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
RU2627451C9 (ru) Противовоспалительные композиции
KR20010033484A (ko) 각질세포 성장 인자-2 제제
CZ154498A3 (cs) Použití proteinového produktu GDNF-faktoru k přípravě farmaceutických přípravků pro léčbu poškození nebo degenerace fotoreceptorů
WO2013097704A1 (zh) 多肽在制备治疗或预防类风湿性关节炎药物中的应用
JP2025163025A5 (cg-RX-API-DMAC7.html)
WO2022002186A1 (zh) 用于修复黏膜损伤或皮肤创伤的多肽及其应用
Shao et al. An EPO‐loaded multifunctional hydrogel synergizing with adipose‐derived stem cells restores neurogenic erectile function via enhancing nerve regeneration and penile rehabilitation
NO329488B1 (no) Anvendelse av neurotrofin-3 ved fremstilling av et medikament til behandling av gastrointestinale hypomotilitetslidelser.
KR101825041B1 (ko) 물질 p를 포함하는 상처치유용 약학 조성물
JP2023515915A5 (cg-RX-API-DMAC7.html)
TW200302108A (en) New peptides and their pharmaceutical use
CN114773428A (zh) 新多肽及其在制备治疗皮肤创面或黏膜损伤药物中的应用
CN118184735A (zh) 一类具有诱导Treg作用的多肽及其在治疗自身免疫性疾病中的应用
CN118027175A (zh) 冻存prp与干细胞外泌体治疗无菌性炎症疾病
GB2600845A (en) Recombinant fusion polypeptide and use thereof
CN111569046B (zh) 多肽在制备治疗胰腺炎药物中的用途及含有其的药物
HUT67217A (en) Remedy for airway diseases
MXPA06012175A (es) Promotor de neuritogenesis corneal que contiene polipeptido activador de la adenilato ciclasa de la pituitaria y sus derivados.
CN114805489A (zh) 一类用于修复皮肤损伤或黏膜损伤的多肽及其应用
US20040038907A1 (en) Angiogenic agents and their uses
CN105801684B (zh) 重组人生长激素及其促进卵泡发育的应用
CN110577942A (zh) 一种用于提高视网膜色素上皮细胞吞噬功能的活性肽及其应用
CN111358937A (zh) Fgf-2衍生多肽在制备促进软骨修复和/或治疗骨关节炎药物中的用途
RU2694906C2 (ru) Пептиды производные эзрина и фармацевтические композиции на их основе